Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Simon Law Firm PC
If you purchased the Breathe Right Snore Relief throat spray manufactured by GlaxoSmithKline, you could receive compensation from a class action settlement.
ST. LOUIS, March 21, 2013 /PRNewswire/ -- A settlement has been reached in a class action lawsuit against GlaxoSmithKline. The lawsuit alleges that Defendant GlaxoSmithKline falsely and deceptively marketed its Breathe Right Snore Relief throat spray. Defendant denies the allegations in this lawsuit and asserts it has not violated any laws. To avoid further litigation, the Parties have reached a class action settlement, which was preliminarily approved by the Circuit Court of St. Clair County, Illinois.
Under the terms of the settlement, you may be entitled to compensation if you purchased Defendant's Breathe Right Snore Relief throat spray in the State of Illinois from January 1, 2008 through the present. Excluded from the class are Defendant and its officers, directors, shareholders, partners, and owners; the Court presiding over any motion to approve this Settlement Agreement; and those persons who timely and validly request exclusion from the Settlement Class.
What Does The Settlement Provide? Settlement Class Members may submit a properly completed Claim Form and be eligible to receive Voucher or card in the amount of up to $8.00 that can be used the same as cash at retail stores in Illinois that sell Defendant's products for the purchase of "Breathe Right Nasal Strips".
How Do You Submit A Claim? To qualify for payment, you must submit a claim form by May 21, 2013. Claim forms can either be submitted online, at www.ThroatSpraySettlement.com, or can be obtained by calling 1-888-879-8974.
What Are Your Other Options? If you don't want to be legally bound by the settlement, you must exclude yourself ("opt-out") by May 21, 2013. The detailed notice (available at www.ThroatSpraySettlement.com or by calling 1-888-879-8974 explains how to exclude yourself from the settlement. If you exclude yourself, you will not get any settlement payment and you cannot object to the settlement. You also will not be bound by the settlement and may be able to sue (or continue to sue) GlaxoSmithKline regarding the claims in this lawsuit.
If you're a class member, you may object to any part of the settlement you don't like, and the Court will consider your views. You must submit any objection in writing and must provide evidence of your membership in the Class. The procedures for submitting written objections are set out in the detailed notice (available at www.ThroatSpraySettlement.com or by calling 1-888-879-8974).
The Court will hold a Final Fairness Hearing at 9:00 a.m. on June 24, 2013 in Belleville, Illinois. At this hearing, the Court will consider whether the settlement is fair, reasonable and adequate, and whether to approve the class representatives' incentive award in the total amount of $2,000, and attorneys' fees and expenses in the amount of $50,000. You may attend the hearing, and you may hire your own lawyer, but you are not required to do so. If there are objections that have been submitted in writing in advance of the hearing, the Court will consider them. The Court will listen to people who have made a prior written request to speak at the hearing. After the hearing, the Court will decide whether to approve the settlement.
What To Do If You Have Questions. This Notice is just a summary. Detailed notice, as well as the Settlement Agreement and some other documents filed in this lawsuit, can be found online at www.ThroatSpraySettlement.com. You also may call or write to the Throat Spray Settlement Administrator at 1-888-879-8974 or PO Box 3614, Minneapolis, MN 55403-0614 for more information.
QUESTIONS? CALL 1-888-879-8974 or VISIT www.ThroatSpraySettlement.com
MEDIA: Ryan Keane, 314-241-2929
©2012 PR Newswire. All Rights Reserved.